Imperial College London

DrRuthPeters

Faculty of MedicineSchool of Public Health

Honorary Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 8974r.peters

 
 
//

Location

 

Stadium HouseWhite City Campus

//

Summary

 

Publications

Publication Type
Year
to

174 results found

Juraschek SP, Hu J-R, Cluett JL, Ishak AM, Mita C, Lipsitz LA, Appel LJ, Beckett NS, Coleman RL, Cushman WC, Davis BR, Grandits G, Holman RR, Miller ER, Peters R, Staessen JA, Taylor AA, Thijs L, Wright JT, Mukamal KJet al., 2023, Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis., JAMA, Vol: 330, Pages: 1459-1471

IMPORTANCE: There are ongoing concerns about the benefits of intensive vs standard blood pressure (BP) treatment among adults with orthostatic hypotension or standing hypotension. OBJECTIVE: To determine the effect of a lower BP treatment goal or active therapy vs a standard BP treatment goal or placebo on cardiovascular disease (CVD) or all-cause mortality in strata of baseline orthostatic hypotension or baseline standing hypotension. DATA SOURCES: Individual participant data meta-analysis based on a systematic review of MEDLINE, EMBASE, and CENTRAL databases through May 13, 2022. STUDY SELECTION: Randomized trials of BP pharmacologic treatment (more intensive BP goal or active agent) with orthostatic hypotension assessments. DATA EXTRACTION AND SYNTHESIS: Individual participant data meta-analysis extracted following PRISMA guidelines. Effects were determined using Cox proportional hazard models using a single-stage approach. MAIN OUTCOMES AND MEASURES: Main outcomes were CVD or all-cause mortality. Orthostatic hypotension was defined as a decrease in systolic BP of at least 20 mm Hg and/or diastolic BP of at least 10 mm Hg after changing position from sitting to standing. Standing hypotension was defined as a standing systolic BP of 110 mm Hg or less or standing diastolic BP of 60 mm Hg or less. RESULTS: The 9 trials included 29 235 participants followed up for a median of 4 years (mean age, 69.0 [SD, 10.9] years; 48% women). There were 9% with orthostatic hypotension and 5% with standing hypotension at baseline. More intensive BP treatment or active therapy lowered risk of CVD or all-cause mortality among those without baseline orthostatic hypotension (hazard ratio [HR], 0.81; 95% CI, 0.76-0.86) similarly to those with baseline orthostatic hypotension (HR, 0.83; 95% CI, 0.70-1.00; P = .68 for interaction of treatment with baseline orthostatic hypotension). More intensive BP treatment or active therapy lowered risk of CVD or all-cause mortality among

Journal article

Kootar S, Huque MH, Kiely KM, Anderson CS, Jorm L, Kivipelto M, Lautenschlager NT, Matthews F, Shaw JE, Whitmer RA, Peters R, Anstey KJet al., 2023, Study protocol for development and validation of a single tool to assess risks of stroke, diabetes mellitus, myocardial infarction and dementia: DemNCD-Risk., BMJ Open, Vol: 13

INTRODUCTION: Current efforts to reduce dementia focus on prevention and risk reduction by targeting modifiable risk factors. As dementia and cardiometabolic non-communicable diseases (NCDs) share risk factors, a single risk-estimating tool for dementia and multiple NCDs could be cost-effective and facilitate concurrent assessments as compared with a conventional single approach. The aim of this study is to develop and validate a new risk tool that estimates an individual's risk of developing dementia and other NCDs including diabetes mellitus, stroke and myocardial infarction. Once validated, it could be used by the public and general practitioners. METHODS AND ANALYSIS: Ten high-quality cohort studies from multiple countries were identified, which met eligibility criteria, including large representative samples, long-term follow-up, data on clinical diagnoses of dementia and NCDs, recognised modifiable risk factors for the four NCDs and mortality data. Pooled harmonised data from the cohorts will be used, with 65% randomly allocated for development of the predictive model and 35% for testing. Predictors include sociodemographic characteristics, general health risk factors and lifestyle/behavioural risk factors. A subdistribution hazard model will assess the risk factors' contribution to the outcome, adjusting for competing mortality risks. Point-based scoring algorithms will be built using predictor weights, internally validated and the discriminative ability and calibration of the model will be assessed for the outcomes. Sensitivity analyses will include recalculating risk scores using logistic regression. ETHICS AND DISSEMINATION: Ethics approval is provided by the University of New South Wales Human Research Ethics Committee (UNSW HREC; protocol numbers HC200515, HC3413). All data are deidentified and securely stored on servers at Neuroscience Research Australia. Study findings will be presented at conferences and published in peer-reviewed journals. The tool w

Journal article

Lennon MJ, Lam BCP, Lipnicki DM, Crawford JD, Peters R, Schutte AE, Brodaty H, Thalamuthu A, Rydberg-Sterner T, Najar J, Skoog I, Riedel-Heller SG, Roehr S, Pabst A, Lobo A, De-la-Camara C, Lobo E, Bello T, Gureje O, Ojagbemi A, Lipton RB, Katz MJ, Derby CA, Kim KW, Han JW, Oh DJ, Rolandi E, Davin A, Rossi M, Scarmeas N, Yannakoulia M, Dardiotis T, Hendrie HC, Gao S, Carriere I, Ritchie K, Anstey KJ, Cherbuin N, Xiao S, Yue L, Li W, Guerchet MM, Preux P-M, Aboyans V, Haan MN, Aiello AE, Ng TP, Nyunt MSZ, Gao Q, Scazufca M, Sachdev PSSet al., 2023, Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life An Individual Participant Data Meta-Analysis, JAMA NETWORK OPEN, Vol: 6, ISSN: 2574-3805

Journal article

Kootar S, Huque MH, Eramudugolla R, Rizzuto D, Carlson MC, Odden MC, Lopez OL, Qiu C, Fratiglioni L, Han SD, Bennett DA, Peters R, Anstey KJet al., 2023, Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations, JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, Vol: 10, Pages: 478-487, ISSN: 2274-5807

Journal article

Huque MH, Kootar S, Eramudugolla R, Han SD, Carlson MC, Lopez OL, Bennett DA, Peters R, Anstey KJet al., 2023, CogDrisk, ANU-ADRI, CAIDE, and LIBRA Risk Scores for Estimating Dementia Risk., JAMA Netw Open, Vol: 6

IMPORTANCE: While the Australian National University-Alzheimer Disease Risk Index (ANU-ADRI), Cardiovascular Risk Factors, Aging, and Dementia (CAIDE), and Lifestyle for Brain Health (LIBRA) dementia risk tools have been widely used, a large body of new evidence has emerged since their publication. Recently, Cognitive Health and Dementia Risk Index (CogDrisk) and CogDrisk for Alzheimer disease (CogDrisk-AD) risk tools have been developed for the assessment of dementia and AD risk, respectively, using contemporary evidence; comparison of the relative performance of these risk tools is limited. OBJECTIVE: To evaluate the performance of CogDrisk, ANU-ADRI, CAIDE, LIBRA, and modified LIBRA (LIBRA with age and sex estimates from ANU-ADRI) in estimating dementia and AD risks (with CogDrisk-AD and ANU-ADRI). DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study obtained data from the Rush Memory and Aging Project (MAP), the Cardiovascular Health Study Cognition Study (CHS-CS), and the Health and Retirement Study-Aging, Demographics and Memory Study (HRS-ADAMS). Participants who were free of dementia at baseline were included. The factors were component variables in the risk tools that included self-reported baseline demographics, medical risk factors, and lifestyle habits. The study was conducted between November 2021 and March 2023, and statistical analysis was performed from January to June 2023. MAIN OUTCOMES AND MEASURES: Risk scores were calculated based on available factors in each of these cohorts. Area under the receiver operating characteristic curve (AUC) was calculated to measure the performance of each risk score. Multiple imputation was used to assess whether missing data may have affected estimates for dementia risk. RESULTS: Among the 6107 participants in 3 validation cohorts included for this study, 2184 participants without dementia at baseline were available from MAP (mean [SD] age, 80.0 [7.6] years; 1606 [73.5%] female), 548 participants

Journal article

Walsh S, Govia I, Peters R, Richard E, Stephan BC, Wilson N-A, Wallace L, Anstey KJ, Brayne Cet al., 2023, Authors' response to: A new dementia prevention approach requires new language., Alzheimers Dement, Vol: 19, Pages: 3750-3751

Journal article

Walsh S, Govia I, Peters R, Richard E, Stephan BCM, Wilson N-A, Wallace L, Anstey KJ, Brayne Cet al., 2023, What would a population-level approach to dementia risk reduction look like, and how would it work?, ALZHEIMERS & DEMENTIA, Vol: 19, Pages: 3203-3209, ISSN: 1552-5260

Journal article

Xu Y, Aung HLJ, Bateman RJS, Brooks WS, Chhatwal JS, Day GSM, Fagan AMR, Farlow MR, Gordon BG, Kehoe PG, Levin J, Mori HC, Morris JC, Wharton W, Humburg PR, Schofield PR, Peters Ret al., 2023, Higher systolic blood pressure in early-mid adulthood is associated with poorer cognitive performance in those with a dominantly inherited Alzheimer's disease mutation but not in non-carriers. Results from the DIAN study, ALZHEIMERS & DEMENTIA, ISSN: 1552-5260

Journal article

Wilson N-A, Peters R, Lautenschlager NTT, Anstey KJJet al., 2023, Testing times for dementia: a community survey identifying contemporary barriers to risk reduction and screening, ALZHEIMERS RESEARCH & THERAPY, Vol: 15

Journal article

Xu Y, Bouliotis G, Beckett NS, Antikainen RL, Anderson CS, Bulpitt CJ, Peters Ret al., 2023, Left ventricular hypertrophy and incident cognitive decline in older adults with hypertension, JOURNAL OF HUMAN HYPERTENSION, Vol: 37, Pages: 307-312, ISSN: 0950-9240

Journal article

Xu Y, Phu J, Aung HL, Hesam-Shariati N, Keay L, Tully PJ, Booth A, Anderson CS, Anstey KJ, Peters Ret al., 2023, Frequency of coexistent eye diseases and cognitive impairment or dementia: a systematic review and meta-analysis, EYE, ISSN: 0950-222X

Journal article

Peters R, Anderson C, 2023, BLOOD PRESSURE, ANTIHYPERTENSIVES AND DEMENTIA, AN INDIVIDUAL PATIENT DATA META-ANALYSIS, 29th Scientific Meeting of the International Society of Hypertension (ISH), Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: E15-E16, ISSN: 0263-6352

Conference paper

Chong TWH, Rego T, Lai R, Westphal A, Pond CD, Curran E, Kootar S, Peters R, Anstey KJ, Lautenschlager NTet al., 2023, Preferences and Perspectives of Australian General Practitioners Towards a New "Four-in-One" Risk Assessment Tool for Preventative Health: The LEAD! GP Project, JOURNAL OF ALZHEIMERS DISEASE, Vol: 94, Pages: 801-814, ISSN: 1387-2877

Journal article

Huque H, Eramudugolla R, Chidiac B, Ee N, Ehrenfeld L, Matthews FE, Peters R, Anstey KJet al., 2023, Could Country-Level Factors Explain Sex Differences in Dementia Incidence and Prevalence? A Systematic Review and Meta-Analysis, JOURNAL OF ALZHEIMERS DISEASE, Vol: 90, Pages: 1231-1241, ISSN: 1387-2877

Journal article

Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C, Chalmers J, Forette F, Gong J, Harris K, Humburg P, Matthews FE, Staessen JA, Thijs L, Tzourio C, Warwick J, Woodward M, Anderson CSet al., 2022, Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis, EUROPEAN HEART JOURNAL, Vol: 43, Pages: 4980-4990, ISSN: 0195-668X

Journal article

Xu Y, Warwick J, Eramudugolla R, Huque H, Anstey KJ, Peters Ret al., 2022, No clear associations between subjective memory concerns and subsequent change in cognitive function: the PATH through life study, EUROPEAN JOURNAL OF AGEING, Vol: 19, Pages: 1181-1188, ISSN: 1613-9372

Journal article

Xu Y, Warwick J, Eramudugolla R, Huque H, Anstey KJ, Peters Ret al., 2022, No clear associations between subjective memory concerns and subsequent change in cognitive function: the PATH through life study., Eur J Ageing, Vol: 19, Pages: 1181-1188, ISSN: 1613-9372

The literature on subjective memory concerns (SMC) as a predictor for future cognitive decline is varied. Furthermore, recent research has pointed to additional complexity arising from variability in the experience of SMC themselves (i.e. whether they are remitting or sustained over time). We investigated the associations between SMC and objectively measured cognition in an Australian population-based cohort. Four waves (4-year intervals between waves) of data from 1236 participants (aged 62.4 ± 1.5 years, 53% male) were used. We categorized participants as experiencing SMC, when they indicated that their memory problems might interfere with their day-to-day life and/or they had seen a doctor about their memory. SMC was categorized as "no" reported SMC, "remitting", "new-onset" or "sustained" SMC. Cognitive assessment of immediate and delayed recall, working memory, psychomotor speed, attention and processing speed were assessed using a neuropsychological battery. Eighteen percent of participants were characterised as having SMC: 6% (77) "remitting", 6% (77) "new-onset" and 6% (69) "sustained" SMC. There was no consistent evidence for an association between SMC and subsequent decline in cognition. However, SMC was associated with poorer performance on contemporaneous tasks of attention and processing speed compared to "no" SMC. Asking about SMC may indicate a current decline in cognitive function but, in this sample at least, did not indicate an increased risk of future decline.

Journal article

Jicha GA, Abner EL, Arnold SE, Carrillo MC, Dodge HH, Edland SD, Fargo KN, Feldman HH, Goldstein LB, Hendrix J, Peters R, Robillard JM, Schneider LS, Titiner JR, Weber CJet al., 2022, Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report, ALZHEIMERS & DEMENTIA, Vol: 18, Pages: 1109-1118, ISSN: 1552-5260

Journal article

Chong TWH, Kootar S, Wilding H, Berriman S, Curran E, Cox KL, Bahar-Fuchs A, Peters R, Anstey KJ, Bryant C, Lautenschlager NTet al., 2022, Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review, THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, Vol: 12, ISSN: 2045-1253

Journal article

Peters R, Xu Y, Eramudugolla R, Sachdev PS, Cherbuin N, Tully PJ, Mortby ME, Anstey KJet al., 2022, Diastolic Blood Pressure Variability in Later Life May Be a Key Risk Marker for Cognitive Decline, HYPERTENSION, Vol: 79, Pages: 1037-1044, ISSN: 0194-911X

Journal article

Lancaster K, Xu Y, Savage G, Cysique LA, Peters Ret al., 2022, Blood pressure change and cognition in childhood and early adulthood: a systematic review, THERAPEUTIC ADVANCES IN CHRONIC DISEASE, Vol: 13, ISSN: 2040-6223

Journal article

Peters R, Dodge HH, James S, Jicha GA, Meyer P-F, Richards M, Smith AD, Yassine HN, Abner E, Hainsworth AH, Kehoe PG, Beckett N, Anderson CS, Anstey KJet al., 2022, The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?, ALZHEIMERS & DEMENTIA, Vol: 18, Pages: 507-512, ISSN: 1552-5260

Journal article

Chowdhary N, Barbui C, Anstey KJ, Kivipelto M, Barbera M, Peters R, Zheng L, Kulmala J, Stephen R, Ferri CP, Joanette Y, Wang H, Comas-Herrera A, Alessi C, Suharya Dy K, Mwangi KJ, Petersen RC, Motala AA, Mendis S, Prabhakaran D, Bibi Mia Sorefan A, Dias A, Gouider R, Shahar S, Ashby-Mitchell K, Prince M, Dua Tet al., 2022, Reducing the Risk of Cognitive Decline and Dementia: WHO Recommendations, FRONTIERS IN NEUROLOGY, Vol: 12, ISSN: 1664-2295

Journal article

Anstey KJ, Zheng L, Peters R, Kootar S, Barbera M, Stephen R, Dua T, Chowdhary N, Solomon A, Kivipelto Met al., 2022, Dementia Risk Scores and Their Role in the Implementation of Risk Reduction Guidelines, FRONTIERS IN NEUROLOGY, Vol: 12, ISSN: 1664-2295

Journal article

Walsh S, Govia I, Wallace L, Richard E, Peters R, Anstey KJ, Brayne Cet al., 2022, A whole-population approach is required for dementia risk reduction, LANCET HEALTHY LONGEVITY, Vol: 3, Pages: E6-E8, ISSN: 2666-7568

Journal article

Keay L, Ren K, Nguyen H, Vajdic C, Odutola M, Gyawali R, Toomey M, Peters R, Ee N, Dillon L, Hackett M, Ah Tong B, D'Esposito F, Faulmann D, Burton M, Ramke J, Jalbert Iet al., 2022, Risk factors common to leading eye health conditions and major non-communicable diseases: a rapid review and commentary, F1000Research, Vol: 11, ISSN: 2046-1402

Background: To gain an understanding of the intersection of risk factors between the most prevalent eye health conditions that are associated with vision impairment and non-communicable diseases (NCDs). Methods: A series of rapid reviews of reviews reporting on non-modifiable risk factors, age and sex, and modifiable risk factors, including social determinants, were conducted for five common eye health conditions that are the leading causes of vision impairment globally (refractive error including uncorrected refractive error, cataract, age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy) and five prevalent NCDs (cancer, cardiovascular disease, chronic respiratory disease, dementia, and depressive disorders). Articles published within approximately 5 years to the end of 2019 were identified through expert recommendation, PubMED, Ovid Medline, the Lancet Global Burden of Disease series, the International Agency for Research on Cancer and World Cancer Research Fund.    Results: Of 9,213 records identified, 320 records were eligible. Eye health conditions and NCDs share many risk factors. Increased age was found to be the most common shared risk factor, associated with increased risks of AMD, cataract, diabetic retinopathy, glaucoma, refractive error, cancer, cardiovascular disease, chronic obstructive pulmonary disease, and dementia. Other shared risk factors included smoking, obesity, alcohol consumption (mixed results), and physical activity was protective, though limited evidence was found for eye conditions. Social determinants are well documented as risk factors for NCDs. Conclusion: There is substantial overlap in common established risk factors for the most frequent vision impairing eye conditions and leading NCDs. Increasing efforts should be made to integrate preventative and risk reduction interventions to improve health, with greatest shared benefits for initiatives which aim to reduce smoking, improve diet, and promote phys

Journal article

Anstey KJ, Kootar S, Huque MH, Eramudugolla R, Peters Ret al., 2022, Development of the CogDrisk tool to assess risk factors for dementia, ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, Vol: 14

Journal article

Lewis ET, Williamson M, Lewis LP, Chroinin DN, Dent E, Ticehurst M, Peters R, Macniven R, Cardona Met al., 2022, The Feasibility of Deriving the Electronic Frailty Index from Australian General Practice Records, CLINICAL INTERVENTIONS IN AGING, Vol: 17, Pages: 1589-1598

Journal article

Lewis ET, Howard L, Cardona M, Radford K, Withall A, Howie A, Rockwood K, Peters Ret al., 2021, Frailty in Indigenous Populations: A Scoping Review, FRONTIERS IN PUBLIC HEALTH, Vol: 9

Journal article

de Heus RAA, Tzourio C, Lee EJL, Opozda M, Vincent AD, Anstey KJ, Hofman A, Kario K, Lattanzi S, Launer LJ, Ma Y, Mahajan R, Mooijaart SP, Nagai M, Peters R, Turnbull D, Yano Y, Claassen JAHR, Tully PJet al., 2021, Association Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis, HYPERTENSION, Vol: 78, Pages: 1478-1489, ISSN: 0194-911X

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00168342&limit=30&person=true